Inify selects Milton Park as first UK base to deliver AI-powered cancer diagnostics

Swedish company, which speeds up prostate cancer diagnosis, chooses Milton Park for its first UK laboratory

7 Oct 2025

Inify team outside their custom-built, AI-enabled laboratory at Milton Park

Milton Park in Oxfordshire, UK, has welcomed Inify Laboratories Limited as the second occupier at its award-winning Nebula development, with the Swedish digital pathology and AI cancer diagnostics company selecting the innovation community for its first UK laboratory.

Inify’s custom-built, AI-enabled laboratory will help it to meet the UK’s rising demand for cancer diagnostics, while easing pressure on NHS pathology services.

The company's move to Milton Park aims to replicate its recent success in Sweden, which sees it handle around 80% of Stockholm’s and 10% of the country’s total number of prostate biopsies.

Compared to NHS patients often waiting two to three weeks for results in the UK, Inify’s tests in Sweden guarantee an answer in five working days or less, with an average turnaround of just 3.5 days.

As well as the speed of results, Inify says its proprietary AI software, INIFY® Prostate, has been proven in clinical studies to deliver world-leading accuracy, with >99% sensitivity and 97% specificity. Every case is then reviewed by a specialist pathologist before a final report is issued.

The new facility at Milton Park brings Inify’s clinical, laboratory and commercial functions together into a single building. The design of the new laboratory space allows the company to control every stage of its diagnostic chain, from sample logistics, tissue processing and preparation, through to digitisation, AI analysis and review by specialist pathologists.

Kate Bucknall, Managing Director of Inify UK, said, “Our new base at Milton Park is a real milestone in our mission to improving cancer care and reducing delays in patient pathways. Our recent success shows that digitized, AI-supported workflows can halve the time from biopsy to diagnosis, which has been transformative for both patients and clinicians in Sweden".

“With around 120,000 prostate biopsy patients requiring support every year, the UK’s demand for diagnostics is around six times larger than in Sweden. In the UK, our ageing population, growing awareness and a national shortage of pathologists and biomedical scientists mean we have a significant bottleneck in prostate diagnosis.

We want to tackle that challenge head-on in our new facility, by giving patients answers as soon as possible, while providing quality and efficiency gains across the pathway. The Inify lab will have capacity to handle a volume similar to the country’s total demand,” she added.

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>

Tags